What Ultibro Treats: Main Uses and Benefits

Ultibro is commonly used to provide support for chronic symptom management in adult patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). It is a long-term maintenance management strategy applied in conditions where symptoms may intensify temporarily, such as chronic bronchitis and emphysema.

---

Key Therapeutic Focus

The medication helps address symptoms related to heightened physiological activity, specifically persistent breathing difficulty, shortness of breath (dyspnea), and chest tightness. It is relevant in contexts involving heightened systemic burden, generally for individuals with moderate-to-severe breathing difficulty who may require a dual bronchodilator strategy for symptom management.

Long-term use may contribute to maintaining functional stability and is associated with helping to ease the overall symptom burden linked to acute or episodic changes (exacerbations). This supportive relief assists with maintaining functional stability and supports general well-being during symptomatic phases. This treatment is commonly used for ongoing daily control and is not applied for the relief of sudden, acute attacks of breathlessness.

---

Quick Fact: This long-term strategy supports management of persistent breathing difficulty and is used in conditions where symptoms may intensify temporarily.

Regulatory References

1. European Medicines Agency (EMA) overview

Who Can and Cannot Use Ultibro?

Category	Official Eligibility Status
Approved Population	Adult patients (18 years and older) for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
Absolute Contraindications	Use is prohibited for treating acute episodes of bronchospasm (rescue therapy). It is contraindicated in patients with a known hypersensitivity to any component or as monotherapy for asthma.
Age-Related Rule	Use is not established or recommended for the pediatric population (under 18 years). Geriatric patients (65+ years) require no special dose adjustment.
Organ & Condition Restrictions	Use in severe renal impairment (e.g., dialysis patients) is restricted and only recommended if the expected benefit outweighs the potential risk. Caution is advised for patients with severe hepatic impairment, certain cardiovascular disorders, narrow-angle glaucoma, or urinary retention.
Reproductive Status	Use is not recommended during pregnancy or while breastfeeding, unless the expected maternal benefit is deemed to justify the potential risk.

---

Connection to the Overall Eligibility Profile

Regulatory documents establish the adult COPD patient as the sole eligible population, while imposing absolute exclusion for patients with asthma or those requiring acute rescue therapy. Eligibility is further constrained by specific organ function status and reproductive status, limiting or prohibiting use in patients with severe renal impairment, pregnant women, and the pediatric population.

Interactions with other medicines and products

Ultibro (indacaterol/glycopyrronium) may interact with certain other medicines, primarily due to additive pharmacological effects and specific metabolic pathways.

Contraindicated and Not Recommended Combinations

Classification	Interacting Agents	Rationale
Not Recommended	Other Long-Acting Beta-Adrenergic Agonists (LABAs)	Potential for excessive sympathomimetic effects.
Avoid	Other Anticholinergics (LAMAs, SAMAs)	Risk of additive anticholinergic effects (e.g., urinary retention).

---

Pharmacodynamic and Metabolic Interactions

Ultibro should be used with caution when taken with certain drug classes:

• Beta-adrenergic Blockers: May diminish the bronchodilatory effect of indacaterol and should only be used if compelling reasons exist.
• Hypokalaemia-Inducing Agents: Concomitant use with xanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the risk of hypokalemia.
• QTc-Prolonging Drugs: Caution is advised with MAO inhibitors and tricyclic antidepressants due to the potential to amplify effects on the cardiovascular system.
• Strong Inhibitors (e.g., ketoconazole): Medicines that inhibit the CYP3A4 enzyme and P-glycoprotein (P-gp) transport system increase the exposure of indacaterol, though this is generally not considered clinically significant.

Population-Specific Notes

Patients with severe renal impairment have shown increased exposure to the glycopyrronium component. Use in this population requires a careful assessment of benefits versus potential risks.

The mechanism of action for this fixed-dose combination involves the coordinated modulation of the two primary physiological systems that regulate airway smooth muscle tone, and alters the muscle tone, leading to the physiological effect of airway widening.

Direct Modulation of the Adrenergic Pathway

This domain covers the action of Indacaterol, which acts as a long-acting partial agonist at the beta2-adrenergic receptors (beta2-ARs) located on the airway smooth muscle. Activation of these receptors initiates a signal transduction cascade that increases intracellular cAMP (cyclic adenosine monophosphate). This molecular change ultimately leads to a reduction of intracellular calcium in the muscle cells, which results in active smooth muscle relaxation.

️ Inhibiting the Cholinergic Contractile Signal

This domain covers the action of Glycopyrronium, a high-affinity competitive antagonist (blocker) at the M3 muscarinic receptors ( M3). These receptors mediate the primary nerve-driven signal for airway contraction. By blocking the binding of acetylcholine (ACh) to M3, Glycopyrronium prevents the initiation of the contraction cascade, which alters the basal contractile tone of the airways.

Complementary Bronchodilatory Synergy

The mechanisms of Indacaterol and Glycopyrronium are complementary because they target the two non-overlapping regulatory pathways: one actively promoting relaxation (adrenergic) and the other inhibiting contraction (cholinergic). This dual-pathway approach engages both regulatory systems, contributing to a robust and persistent physiological change in airway diameter. The mechanism is functionally limited to the modulation of reversible muscle tone and does not affect fixed structural airway changes.

How Ultibro is Used

Ultibro (Indacaterol and Glycopyrronium) is a fixed-dose combination medicine administered exclusively as a powder for oral inhalation for the long-term, continuous maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. The medicine is not intended for the rapid relief of sudden, acute breathing symptoms (rescue use).

---

Standard Administration and Dosing

The standard regimen involves inhaling the content of one dual-active capsule, delivered directly to the lungs using the dedicated Breezhaler or Neohaler dry powder inhaler device. The capsule must not be swallowed. Administration is independent of food.

Official frequency varies based on the regional formulation strength, though in all cases, the prescribed maximum daily dose must not be exceeded:

Regional Strength (Delivered Dose)	Administration Frequency
85mu g / 43mu g (Indacaterol/Glycopyrronium)	Once daily
27.5mu g / 15.6mu g (Indacaterol/Glycopyrronium)	Twice daily (morning and evening)

---

Usage Guidelines

• Missed Dose: If a dose is missed, it should be taken as soon as possible on the same day. Do not take a double dose to make up for the missed one.
• Co-Use Restriction: The medicine must not be used with other products containing long-acting beta-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs).
• Population Rules: No dose adjustment is required for older adults (geriatric population) or those with mild-to-moderate hepatic or renal impairment. Use in severe renal impairment requires a careful benefit-risk assessment.

Research Evidence / Overview of Studies for Ultibro (Indacaterol/Glycopyrronium)

---

Evidence from Clinical Trials for COPD Maintenance

The clinical evaluation for Ultibro in the long-term management of Chronic Obstructive Pulmonary Disease (COPD) research has primarily used multiple large-scale Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and how breathing function is measured. The research examined adult patients diagnosed with moderate-to-severe COPD. Findings describe patterns where the combination of the two active ingredients was associated with distinct measurement patterns for lung function compared to the individual components alone, as observed in some studies. Research highlights changes measured during the study period, and the data contribute to the broader evidence landscape for maintenance therapy.

While these core studies provide evidence about the short-term and intermediate-term effects on lung function (typically over 12 to 26 weeks), results apply only to the populations studied. Research is ongoing to further contextualize these findings within real-world settings.

---

Research on Exacerbation Rates and Symptom Flare-ups

Specific research trials were conducted focusing on outcomes describing episodic or acute changes, particularly the risk and rate of COPD exacerbations (periods where symptoms become suddenly worse). These long-term comparative studies monitored physiological strain over periods up to a year. Studies explored the pattern of exacerbations when Ultibro was compared to an existing combination treatment (a long-acting beta-agonist and an inhaled corticosteroid, or LABA/ICS). Research describes that the combination was observed to have a different measured rate of these episodes compared to the LABA/ICS pairing in the population studied. Research describes how patients reported their experience when facing conditions characterized by fluctuating or episodic manifestations.

---

Unanswered Questions and Research Gaps

Despite the volume of RCT evidence, certain questions and research gaps exist. Certainty remains low regarding the medicine's use in patients who have certain unstable cardiac conditions, as these patients were typically excluded from the large-scale clinical trials. Additionally, evidence is limited and data for certain groups remain insufficient for patients with severe renal impairment, as research describes a pattern of increased systemic exposure to one component was observed in this group. Furthermore, the medicine was evaluated only in adults, and no research describes its use in the pediatric population (under 18 years of age).

Key Studies & References

1. LAMA-LABA combination versus LAMA or LABA monotherapy for COPD: A systematic review and meta-analysis
2. Summary of evidence from the IGNITE clinical trial program for Indacaterol/Glycopyrronium (LABA/LAMA)

Common questions about Ultibro (FAQ)

Q: How quickly is Ultibro expected to start working after the first dose?

A: Official data indicates that the Indacaterol component of the medicine has a rapid onset of action. This effect is described in official data as beginning within 5 minutes of the first inhalation. The medicine is, however, intended for long-term maintenance and not for immediate rescue use.

Q: What does 'maintenance treatment' mean for this medicine?

A: Maintenance treatment refers to a regular, long-term therapy that is used every day to keep the airways open and relieve chronic symptoms of COPD. It is designed to provide sustained bronchodilation over a full 24-hour period. It is important to note that this is not a rescue medicine and should not be used to treat sudden, acute breathing symptoms.

Q: Is Ultibro a steroid medicine?

A: No, the medicine does not contain an inhaled corticosteroid (steroid). It is defined as a dual bronchodilator because it contains two distinct classes of airway-opening medicines: a long-acting beta-2 agonist (Indacaterol) and a long-acting muscarinic antagonist (Glycopyrronium).

Q: What is the approximate duration of the effect after one use of Ultibro?

A: The medicine is designed to provide sustained airway opening, with an approximate duration of action of 24 hours. This pharmacological effect supports the required once-daily dosing regimen for continuous COPD management.

Q: How long does it usually take to feel the full benefit of Ultibro?

A: Clinical trials describe significant and meaningful improvements in lung function (FEV1) starting as early as Day 1 of treatment. Efficacy was monitored and continued to be observed through long-term study periods of Week 26 and Week 52 of continuous use.

Q: Can Ultibro be used by someone who also takes blood pressure medication?

A: Official product information advises caution when this medicine is used with certain types of heart or blood pressure treatments. This includes specific types of Beta-adrenergic blockers, certain diuretics, and medications that may affect the heart's electrical activity. The importance of communicating all current heart and blood pressure medications to the prescribing physician is emphasized in official documents due to these potential interactions.

Q: Are there any specific foods or drinks that should be avoided when using Ultibro?

A: Administration of the medicine is described as being independent of food. However, regulatory documents suggest that the Glycopyrronium component of the medicine may have an interaction with ethanol (alcohol), which could potentially increase side effects such as drowsiness and dizziness. Caution is also noted regarding the use of other substances that belong to the same pharmacological class as caffeine.

Q: Why is Ultibro used for COPD and not for other lung issues?

A: According to official labeling, this medicine is explicitly indicated for the long-term maintenance treatment of airflow obstruction in adult patients with Chronic Obstructive Pulmonary Disease (COPD). It is contraindicated (prohibited) for patients with asthma because one of its components, a long-acting beta-agonist (LABA), may be associated with an increased risk of asthma-related death when used alone in asthma patients.

Q: What is the purpose of the device (inhaler) that Ultibro comes in?

A: Ultibro is supplied as an ultra-fine powder inside a capsule. The device, such as the Breezhaler or Neohaler, is dedicated and required to create a fine powder, which ensures the medicine is delivered directly to the lungs. The specialized design of the dedicated inhaler device facilitates the necessary delivery of the powder directly to the lungs.

Q: What is the difference between Ultibro and other LAMA/LABA combination inhalers?

A: This medicine is a fixed-dose combination (FDC) bronchodilator defined by its two specific active ingredients: Indacaterol and Glycopyrronium. While it belongs to the LAMA/LABA class, other combination inhalers in this class contain different active substances that target the same pathways.

Q: Are there any known issues with alcohol consumption while using Ultibro?

A: Official product information indicates that the active ingredient Glycopyrronium may interact with ethanol (alcohol). This interaction could potentially increase the risk of certain side effects, such as drowsiness and dizziness.

Q: Does Ultibro require any specific training to use correctly?

A: The official product information indicates that the correct administration technique is fundamental to the medicine's delivery. Regulatory documents state that patients are advised to be instructed on how to use their inhaler device and have their technique reviewed by observation.

Storage and Disposal Requirements for Ultibro Breezhaler

Ultibro Breezhaler capsules must be stored in the original sealed blister packaging to ensure protection from moisture and light. The official regulatory requirement is to store the medicine at a temperature not exceeding 30 C. The product must be kept out of the sight and reach of children.

The accompanying Breezhaler device has a specific in-use limit and must be disposed of after 30 days of use. Unused or expired Ultibro must be discarded according to local regulations or returned to a pharmacist for proper disposal; the medicine should not be flushed down a toilet or thrown into general household waste, except for the empty capsule shell after inhalation.